Vhio.netActualidad2010-07-30T14:19:26+01:00vhio.net/plantillas/imgs/logo.jpgtext/html2009-12-23T10:57:00+01:00vhio.netVHIO tests a new combination of drugs for HER2-positive breast cancer without the adverse effects of conventional chemotherapy
http://www.vhio.net/en/current-events/corporative-news/index.php?s=vhio-tests-a-new-combination-of-drugs-for-her2-positive-breast-cancer-without-the-adverse-effects-of-conventional-chemotherapy
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibodytext/html1999-11-30T12:00:00+01:00vhio.netVHIO tries out a new diagnostic test that detects HER2 fragments in breast cancer
http://www.vhio.net/en/current-events/corporative-news/index.php?s=her2-fragments-in-breast-cancer
Approximately 30% of all breast cancers currently diagnosed have a genetic abnormalitytext/html1999-11-30T12:00:00+01:00vhio.netTranslational Research allows the development of personalized treatment for cancer
http://www.vhio.net/en/current-events/corporative-news/index.php?s=translational-research-will-allow-the-development-of-personalized-treatment-for-cancer-1
Today, we know much more about why a cell becomes cancerous and about which proteins and genes are responsible for this happeningtext/html1999-11-30T12:00:00+01:00vhio.netLIF, a gene involved in the proliferation of tumour stem cells
http://www.vhio.net/en/current-events/corporative-news/index.php?s=emlifem-gen-implicat-en-la-proliferacino-de-cnellules-mare-tumorals
The Vall d’Hebron Institute of Oncology (VHIO) has published a new study describing a new molecular mechanism that regulates the renewal of the glioma stem cells. The findings represent an important advancement in the research centred on one of the most aggressive brain tumours, the glioblastoma multiformetext/html1999-11-30T12:00:00+01:00vhio.netTherapeutic targets in pancreatic cancer
http://www.vhio.net/en/current-events/corporative-news/index.php?s=dianes-terapneutiques-per-al-cnancer-2
Davide Melisi will offer a conference about TGF-ß signaling for anticancer therapiestext/html1999-11-30T12:00:00+01:00vhio.netmTOR, cell functions regulator
http://www.vhio.net/en/current-events/corporative-news/index.php?s=mtor-regulador-de-funcions-cellulars
Christopher Proud, from Southampton University, presents the latest advancements related to mTOR, involved in certain cancerstext/html1999-11-30T12:00:00+01:00vhio.netAdvancements in resistance to Tamoxifen
http://www.vhio.net/en/current-events/corporative-news/index.php?s=dianes-terapneutiques-per-al-cnancer-1
Antonio Hurtado, from the Cambridge Research Institute, will offer a seminar on the factors that cause resistance to Tamoxifen on breast cancer patientstext/html1999-11-30T12:00:00+01:00vhio.netThe Translational Biomedicine and Oncology Research Consortium has been created
http://www.vhio.net/en/current-events/corporative-news/index.php?s=se-ha-creado-el-consorcio-de-investigacinon-biomnedica-y-oncolnogica-translacional
It is the first National Agreement that includes the Academic environment, basic research, clinical research and the pharmaceutical industrytext/html1999-11-30T12:00:00+01:00vhio.netGrant for the research in colorectal cancer
http://www.vhio.net/en/current-events/corporative-news/index.php?s=ayuda-para-el-estudio-del-cnancer-colorrectal
The "Olga Torres" Foundation awards to a VHIO research group a grant for the research on tumor stem cellstext/html1999-11-30T12:00:00+01:00vhio.netTherapeutic targets for cancer
http://www.vhio.net/en/current-events/corporative-news/index.php?s=dianes-terapneutiques-per-al-cnancer
Arkaitz Carracedo, from the Harvard Medical School, gives a lecture on the latest developments on potential therapy for cancer